And welcome to this webinar on our Q1 results. We will start with just a few slides on who we are, and then we will try to add a little more detail to the executive summary that we have. And then Andrew will guide us through the financial update. Uh, and then hopefully, lots of questions afterwards. So, let's get rolling. I think you have seen this slide before, but it's always good to repeat what kind of company we are? Because, as we have also addressed in our Q1 report, not the least in the CEO's words, we have tried to simplify our strategy going forward and be more clear that we are the global go-to separations company. And as you also know, we do have quite a lot of products that cover workflow solutions for our customers. That includes instrumentation, consumables, and services. And as you can see in the middle of the slide, we are covering more or less all of the stages there are in drug discovery. So we can cater to most types of customers. And of course, to the right of the slides, you see all the modalities that we have in our pipeline and our product portfolio. So, I think we are pretty well equipped for also seeing some interesting growth going forward. Which brings me to the next slide. Just as an executive summary, as you all have seen. Uh, this morning we came out with a top line of 480 million SEK. A 33% growth over last year with a very impressive gross margin of 63.1%, an uptake of 2.2%. And that we are also pretty good at converting our sales to cash, as you can see, we have converted 171 million SEK and having an adjusted EBITDA of 126 million SEK. Uh, as I also wanted to allude to before we get to Andrew's presentation. There has been tremendous growth in our recurring revenue, which is now up at 72%. Some of you know that in the old days, we were fighting to get to this percent, and we have now moved from 67% out of 2023 and now to 72%. And of course, that has to do with the Biotage business that has grown by 78% over the last Q1 in 2023. And as you can also see, our Advanced Therapeutics and Biologics now cover 30% of our business. So, a very good way of going forward with this, with one caveat that we are not happy with, also mentioned in the report. That was that we didn't succeed in getting the core bioscience to a zero level, or as we said last time, a small increase. And you also know the reason, and in a positive way, we say there is tremendous demand in the peptide business. And we were not able to fulfill that demand. Have we had the opportunity to do that? We would have had very good single-digit growth, even in the core business. We're working on it. We are increasing the capacity going forward. And we are still seeing tremendous growth in the peptide area. We are continuing to invest both in manufacturing facilities and in our R&D capabilities around the globe. So with that, I think I have one more slide which I want to just allude to, just to give you a flavor of that. It's not just our current business. We are also launching new products. And you can see the PuraBead Edge. And one of the things we are also constantly having in our mindset is that we need to continue developing products that can be sustainable. And that we are trying to eliminate, let's say, all the solvents we can. And it goes for both sides of the slides and that we are also bringing more products into the PFAS area, going forward. And hopefully, we will see slides also in the next quarter that are also having some instrumentation out in the field as new products. And by that, I hand over the word to Andrew. Thank you, Torben. The business, as just mentioned, had a good start to the year with a solid Q1 performance. We returned to positive organic growth in our key markets in the Americas and EMEA, and we delivered strong recurring revenues at 72% in the quarter. It's worth just pointing out that Biotage is built on sound fundamental foundations of business focused on the traditional small molecule market, delivers predictable revenue streams, industry-leading gross margins, and solid underlying EBITDA and cash generation. Our Biologics and Advanced Therapeutics business, which incorporates Australia, gives us access to the higher growth pharmaceuticals market and the ability to generate superior revenue growth and attractive margins. And as you just heard, our biologics business in Q1 accounted for 30% of our total revenue compared to just 4% in Q1 2023. Coupled with our expansive modality offering and expertise, a further strength of Biotage is its balanced geographical profile, with strong positions in the Americas and EMEA markets, and attractive plays in selective key Asian markets that offer significant medium-term growth opportunities. And as you just heard, in the quarter, we delivered revenues of 480 million, up 33%, gross margins of 63.1%, up 2.2 percentage points, and underlying EBITDA at 126 million, up 28%. We saw very encouraging double-digit growth in EMEA and smaller positive growth in the Americas. But on the flip side, we saw strong gains in China as well. We've seen a marked recent acceleration in customer demand for equipment targeted at the peptide market, which we have been unable to keep fully pace with in the first quarter. We're actively working with our supply partner to ensure additional production capacity is available so that delivery can take place in the required volumes in the coming quarters. Had it not been for this issue, we would have been able to report some quite nice positive organic growth rather than the small negative organic growth of 1.4% reported. Just a few words on Australia: In Q1, Australia delivered 129 million in revenue and a margin of 64.8% compared to Q1 2023. Revenue grew by 78%. Just to reiterate what I've previously commented, Australia is a growing business and not at a stage where it neatly fits into a stable, uniform quarter format like our small molecules business. Of course, we're very pleased with our Q1 growth, but you cannot take that Q1 growth and assume it applies uniformly to the following quarters. It is still lumpy, but what we can say is that we are on course to deliver very pleasing growth year on year, with current market forecasts appropriately reflecting this. In the quarter, we saw growth in biologics and advanced therapeutics, analytical testing, and water and environmental testing. Our small molecule business saw declines driven by suppressed business activity, with APAC heavily impacting this. Our scale-up and diagnostics businesses, which together represent less than 10% of our business, also declined in Q1 with scale-up. The decline was driven by the comparator, with Q1 '23 containing the last remnants of Covid-related business in China. With the diagnostics business. We were again up against some very strong comparators with a very large customer order delivered in Q1 '23. Order intake in both our scale-up and diagnostics businesses is more lumpy. Therefore, you have to focus more on the medium-term trend rather than a particular quarter. At constant exchange rates excluding Australia. Our EMEA business delivered solid organic revenue growth in the quarter of 10%; our Americas business delivered growth of 2%, while our APAC business saw a negative growth of 17% in Q1, driven by China, excluding China. Our revenue in Q1 was consistent with the prior year. Needless to say, we're actively looking at all our businesses on a routine basis to ensure that we are right-sized to ensure continued prosperity. Headwinds in Q1 '24 held back our organic growth by approximately 5 million SEK, or 1%. If we look at our total group business, including Austria, our EMEA and American markets accounted for 83% of our total business, compared to 72% last year, with APAC accounting for the further 17% or 28% last year. Our recurring revenues were very strong, 346 million, representing 72% of our total revenue, compared to 59% last year, with our non-recurring revenues making up the balance of 134 million, or 28%, compared to 41% last year. Higher recurring revenues give us more predictability in our results. Our guiding principle is always to put the customer first and concentrate on forming long-term partnerships with them to solve their problems, improve their workflows and efficiency, and create additional value. In Q1, we delivered an adjusted EBITDA of 126 million, 28% above Q1 last year. In the quarter, we also took approximately 8 million in charges relating to the CEO transition. And as these are one-off in nature, they have been excluded in deriving the adjusted EBITDA total. We delivered a very strong adjusted cash flow from operations of 171 million, 103 million above the prior year, and we finished the quarter with gross cash of 683 million SEK and net cash of 426 million SEK. Also during the quarter, we continued to invest in R&D to be at the forefront of innovation leadership in our markets. We have an attractive R&D pipeline that will power our future growth. As you've just seen from Torben, we continue to launch exciting new products in the quarter, and we're particularly excited about PuraBead Edge. Adapting novel nanofiber technology platform that addresses the challenges of purifying large and fragile modalities, the fast-growing cell and gene therapy markets. So in summary, Biotage has a strong market position with an enviable broad suite of critical must-have solutions in our key markets of drug discovery and development through to diagnostics and analytical testing. We have a clear strategic vision and are resolutely focused on executing on our plans to deliver superior growth at attractive margins. And just a final reminder to everyone that Biotage will be holding a Capital Markets Day on Thursday, 23rd of May in Cambridge. And we would very much like to see as many people as we can, so we can outline how Biotage is evolving and explain in more detail our exciting technology and growth plans. Back to you, Torben. Now, as you have heard, we are facilitating that we can get some guidance. And I want to reiterate what Andrew just said, that we would absolutely encourage as many of you as can come to Cambridge and first of all, have a presentation of other managers in my team and of course, even more, see the site in Cambridge where you will see some of the fantastic new products we are trying to develop. So, by that, we will open for questions.